| __timestamp | Axsome Therapeutics, Inc. | Sanofi |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 8565000000 |
| Thursday, January 1, 2015 | 2419289 | 9496000000 |
| Friday, January 1, 2016 | 6343648 | 9592000000 |
| Sunday, January 1, 2017 | 7206691 | 10164000000 |
| Monday, January 1, 2018 | 9351522 | 9934000000 |
| Tuesday, January 1, 2019 | 13598030 | 9883000000 |
| Wednesday, January 1, 2020 | 28896749 | 9390000000 |
| Friday, January 1, 2021 | 66646205 | 9555000000 |
| Saturday, January 1, 2022 | 159253661 | 10539000000 |
| Sunday, January 1, 2023 | 323123000 | 10765000000 |
| Monday, January 1, 2024 | 411359000 | 9183000000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, Sanofi and Axsome Therapeutics, Inc. have showcased contrasting trajectories in their SG&A expenditures. From 2014 to 2023, Sanofi's SG&A expenses have remained relatively stable, fluctuating around the $10 billion mark annually. In contrast, Axsome Therapeutics has seen a dramatic increase, with expenses skyrocketing from approximately $1.4 million in 2014 to over $320 million in 2023, marking a staggering growth of over 22,000%. This divergence highlights the different stages and strategies of these companies: Sanofi's mature market presence versus Axsome's aggressive growth phase. As investors and analysts look to the future, these trends offer valuable insights into each company's operational focus and market strategy.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Axsome Therapeutics, Inc.
Novartis AG and Sanofi: SG&A Spending Patterns Compared
Sanofi or Alnylam Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Sanofi or Teva Pharmaceutical Industries Limited
Sanofi or Jazz Pharmaceuticals plc: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Novavax, Inc.